Posted by Michael Wonder on 12 Dec 2019
Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine
11 December 2019 - Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine has received approval from Health Canada for use in people 9 years of age and older.
Marketed as Flucelvax Quad, the vaccine offers protection against four influenza virus strains — A(H3N2), A(H1N1) and two B virus strains.
QIVc is produced using innovative cell-based technology and was first licensed in the U.S. in 2016. All four vaccine-viruses in Flucelvax Quad are grown in MDCK cells, which eliminates the risk of egg adaptation during the manufacturing process. Flucelvax Quad may therefore offer a truer match to World Health Organization recommended vaccine strains than traditional egg-based influenza vaccines, with the potential to provide better protection each season.
